{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:06:24Z","timestamp":1783706784857,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.03.051","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T12:52:09Z","timestamp":1554900729000},"page":"4814-4822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical endpoints for efficacy studies"],"prefix":"10.1016","volume":"37","author":[{"given":"Chad K.","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro L.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Kotloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.03.051_b0005","doi-asserted-by":"crossref","unstructured":"Porter, C.K., et al., Developing and utilizing controlled human models of infection. Vaccine, 2017. 35(49 Pt A): p. 6813-6818.","DOI":"10.1016\/j.vaccine.2017.05.068"},{"issue":"35","key":"10.1016\/j.vaccine.2019.03.051_b0010","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1016\/j.vaccine.2011.05.021","article-title":"A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)","volume":"29","author":"Porter","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.03.051_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149358","article-title":"An evidenced-based scale of disease severity following human challenge with enteroxigenic Escherichia coli","volume":"11","author":"Porter","year":"2016","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.vaccine.2019.03.051_b0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1017\/S0950268812001677","article-title":"The Shigella human challenge model","volume":"141","author":"Porter","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2019.03.051_b0025","unstructured":"Gutierrez R, et al. Progress Towards a Fimbrial Tip Adhesin Vaccine Against Enterotoxigenic E. coli (ETEC). In: World Vaccine Congress. 2016. Washington, DC."},{"issue":"6","key":"10.1016\/j.vaccine.2019.03.051_b0030","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/infdis\/155.6.1260","article-title":"Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine","volume":"155","author":"Black","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.051_b0035","unstructured":"Talaat KR, et al. Flexyn2a, a candidate bioconjugate vaccine against Shigella flexneri 2a induces protective immune response in a controlled human infection model. In: Vaccines for Enteric Diseases. 201Albufeira, Portugal."},{"issue":"3","key":"10.1016\/j.vaccine.2019.03.051_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194325","article-title":"Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score","volume":"13","author":"Porter","year":"2018","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.vaccine.2019.03.051_b0045","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4269\/ajtmh.15-0200","article-title":"Gastrointestinal infections in deployed forces in the middle east theater: an historical 60 year perspective","volume":"93","author":"Riddle","year":"2015","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2019.03.051_b0050","doi-asserted-by":"crossref","first-page":"891","DOI":"10.4269\/ajtmh.2006.74.891","article-title":"Incidence, etiology, and impact of diarrhea among long-term travelers (us military and similar populations): a systematic review","volume":"74","author":"Riddle","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.051_b0055","doi-asserted-by":"crossref","first-page":"762","DOI":"10.4269\/ajtmh.2006.75.762","article-title":"Incidence, etiology, and impact of diarrhea among deployed US military personnel in support of Operation Iraqi Freedom and Operation Enduring Freedom","volume":"75","author":"Monteville","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"10.1016\/j.vaccine.2019.03.051_b0060","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.051_b0065","unstructured":"Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries. In: Wkly Epidemiol Rec. 2006."},{"issue":"8778","key":"10.1016\/j.vaccine.2019.03.051_b0070","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/0140-6736(91)92590-X","article-title":"Prevention of travellers' diarrhoea by oral B-subunit\/whole-cell cholera vaccine","volume":"338","author":"Peltola","year":"1991","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2019.03.051_b0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1473-3099(13)70297-4","article-title":"Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala","volume":"14","author":"Behrens","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"9629","key":"10.1016\/j.vaccine.2019.03.051_b0080","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(08)60839-9","article-title":"Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial","volume":"371","author":"Frech","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2019.03.051_b0085","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.tmaid.2009.09.001","article-title":"Outcomes of diarrhea management in operations Iraqi Freedom and Enduring Freedom","volume":"7","author":"Brown","year":"2009","journal-title":"Travel Med Infect Dis"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2019.03.051_b0090","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/jtm\/tax026","article-title":"Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report","volume":"24","author":"Riddle","year":"2017","journal-title":"J Travel Med"},{"issue":"9888","key":"10.1016\/j.vaccine.2019.03.051_b0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.03.051_b0100","unstructured":"Vidal RM, Muhsen K, Tennant SM, Svennerholm AM, Sow SO, Sur D, et al. Colonization factors among enterotoxigenic Escherichia coli isolates from children with moderate-to-severe diarrhea and from matched controls in the Global Enteric Multicenter Study (GEMS). PLoS Neglected Tropical Diseases."},{"issue":"12","key":"10.1016\/j.vaccine.2019.03.051_b0105","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1086\/386288","article-title":"Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method","volume":"189","author":"Clemens","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.051_b0110","unstructured":"GBD, Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis, 2017."},{"issue":"16","key":"10.1016\/j.vaccine.2019.03.051_b0115","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0264-410X(95)00102-7","article-title":"A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity","volume":"13","author":"Kotloff","year":"1995","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2019.03.051_b0120","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1128\/CVI.05194-11","article-title":"Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines","volume":"18","author":"Harro","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2019.03.051_b0125","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa1706804","article-title":"Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth","volume":"378","author":"Bines","year":"2018","journal-title":"N Engl J Med"},{"issue":"9741","key":"10.1016\/j.vaccine.2019.03.051_b0130","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Armah","year":"2010","journal-title":"Lancet"},{"issue":"45","key":"10.1016\/j.vaccine.2019.03.051_b0135","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1016\/j.vaccine.2017.09.014","article-title":"A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants","volume":"35","author":"Kulkarni","year":"2017","journal-title":"Vaccine"},{"issue":"9741","key":"10.1016\/j.vaccine.2019.03.051_b0140","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Zaman","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.vaccine.2019.03.051_b0145","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1016\/j.vaccine.2007.03.034","article-title":"Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico","volume":"25","author":"Sack","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.051_b0150","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00006454-200204000-00012","article-title":"Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants","volume":"21","author":"Savarino","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.03.051_b0155","unstructured":"Savarino A-E, Rao M, Frenck R, Abdel-Messih I, Hall ER. Efficacy of an oral, inactivated whole-cell enterotoxigenic E. coli\/cholera toxin B subunit vaccine in Egyptian infants, in National Foundation for Infectious Diseases. 2003: Arlington, VA."},{"key":"10.1016\/j.vaccine.2019.03.051_b0160","unstructured":"Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries. Wkly Epidemiol Rec, 2006. 81(11): p. 97\u2013104."},{"issue":"10051","key":"10.1016\/j.vaccine.2019.03.051_b0165","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(16)31529-X","article-title":"Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study","volume":"388","author":"Liu","year":"2016","journal-title":"Lancet"},{"issue":"49 Pt A","key":"10.1016\/j.vaccine.2019.03.051_b0170","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1016\/j.vaccine.2017.07.036","article-title":"Global burden of diarrheal diseases among children in developing countries: Incidence, etiology, and insights from new molecular diagnostic techniques","volume":"35","author":"Kotloff","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2019.03.051_b0175","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1128\/CVI.00364-12","article-title":"The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease","volume":"19","author":"Darsley","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.03.051_b0180","unstructured":"Carlin N, Kantele A, Svennerholm A-M. A Phase 2b clinical trial of ETVAX, an oral whole-cell inactivated vaccine against enterotoxigenic Escherichia coli, in Finnish travelers to Benin. In: Vaccines Against Shigella and ETEC. 2018. Mexico City, Mexico."},{"issue":"12","key":"10.1016\/j.vaccine.2019.03.051_b0185","doi-asserted-by":"crossref","first-page":"e1319","DOI":"10.1016\/S2214-109X(18)30351-6","article-title":"Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study","volume":"6","author":"Rogawski","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"3","key":"10.1016\/j.vaccine.2019.03.051_b0190","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/infdis\/119.3.296","article-title":"The response of man to virulent Shigella flexneri 2a","volume":"119","author":"DuPont","year":"1969","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.051_b0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/infdis\/125.1.12","article-title":"Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection","volume":"125","author":"DuPont","year":"1972","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2019.03.051_b0200","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/infdis\/127.3.261","article-title":"Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery","volume":"127","author":"Levine","year":"1973","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.051_b0205","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/infdis\/136.4.577","article-title":"Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri","volume":"136","author":"Levine","year":"1977","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.03.051_b0210","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/infdis\/159.6.1126","article-title":"Inoculum size in shigellosis and implications for expected mode of transmission","volume":"159","author":"DuPont","year":"1989","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2019.03.051_b0215","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0264-410X(90)90094-3","article-title":"Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease","volume":"8","author":"Herrington","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.051_b0220","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1128\/IAI.60.6.2218-2224.1992","article-title":"Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen","volume":"6","author":"Kotloff","year":"1992","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2019.03.051_b0225","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4269\/ajtmh.1992.47.276","article-title":"Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge","volume":"47","author":"Tacket","year":"1992","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2019.03.051_b0230","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/infdis\/166.5.1181","article-title":"An analysis of the quantitative relationship between oral temperature and severity of illness in experimental shigellosis","volume":"166","author":"Mackowiak","year":"1992","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2019.03.051_b0235","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0264-410X(94)00011-B","article-title":"Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2","volume":"13","author":"Kotloff","year":"1995","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.051_b0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4269\/ajtmh.1995.53.47","article-title":"Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances","volume":"53","author":"Munoz","year":"1995","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"10.1016\/j.vaccine.2019.03.051_b0245","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/IAI.67.7.3437-3443.1999","article-title":"Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602","volume":"67","author":"Coster","year":"1999","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2019.03.051_b0250","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1086\/503039","article-title":"Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge","volume":"42","author":"Taylor","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.051_b0255","unstructured":"Frenck Jr, RW, et al. Development of a S. sonnei controlled human infection model using a lyophilized GMP lot of strain 53G. In: Vaccines for Enteric Diseases. 2017. Albufeira, Portugal."},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.051_b0260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1708-8305.1995.tb00615.x","article-title":"Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell\/Recombinant B Subunit (WC\/rBS) Oral Cholera Vaccine Against Travelers' Diarrhea","volume":"2","author":"Scerpella","year":"1995","journal-title":"J Travel Med"},{"issue":"1","key":"10.1016\/j.vaccine.2019.03.051_b0265","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2310\/7060.2000.00007","article-title":"Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report)","volume":"7","author":"Wiedermann","year":"2000","journal-title":"J Travel Med"},{"issue":"43","key":"10.1016\/j.vaccine.2019.03.051_b0270","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1016\/j.vaccine.2005.05.022","article-title":"Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study","volume":"23","author":"Leyten","year":"2005","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19303858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19303858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:13:28Z","timestamp":1607213608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19303858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":54,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19303858"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical endpoints for efficacy studies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}